224 related articles for article (PubMed ID: 27017851)
1. [Incretin-based antidiabetic treatment and diseases of the pancreas (pancreatitis, pancreas carcinoma)].
Jermendy G
Orv Hetil; 2016 Apr; 157(14):523-8. PubMed ID: 27017851
[TBL] [Abstract][Full Text] [Related]
2. Are incretin mimetics and enhancers linked to pancreatitis and malignant transformations in pancreas?
de Heer J; Göke B
Expert Opin Drug Saf; 2014 Nov; 13(11):1469-81. PubMed ID: 25270593
[TBL] [Abstract][Full Text] [Related]
3. An updated review on cancer risk associated with incretin mimetics and enhancers.
Tseng CH; Lee KY; Tseng FH
J Environ Sci Health C Environ Carcinog Ecotoxicol Rev; 2015; 33(1):67-124. PubMed ID: 25803196
[TBL] [Abstract][Full Text] [Related]
4. A systematic review of acute pancreatitis as an adverse event of type 2 diabetes drugs: from hard facts to a balanced position.
Giorda CB; Nada E; Tartaglino B; Marafetti L; Gnavi R
Diabetes Obes Metab; 2014 Nov; 16(11):1041-7. PubMed ID: 24702687
[TBL] [Abstract][Full Text] [Related]
5. Incretin-based glucose-lowering medications and the risk of acute pancreatitis and/or pancreatic cancer: Reassuring data from cardio-vascular outcome trials.
Nauck MA; Meier JJ; Schmidt WE
Diabetes Obes Metab; 2017 Sep; 19(9):1327-1328. PubMed ID: 28432752
[No Abstract] [Full Text] [Related]
6. Incretin-based pharmacotherapy and risk of adverse pancreatic events in the ethnic Chinese with diabetes mellitus: A population-based study in Taiwan.
Tseng CM; Liao WC; Chang CY; Lee CT; Tseng CH; Hsu YC; Lin JT
Pancreatology; 2017; 17(1):76-82. PubMed ID: 27743712
[TBL] [Abstract][Full Text] [Related]
7. Incretin-based therapies and risk of pancreatic cancer in patients with type 2 diabetes: A meta-analysis of randomized controlled trials.
Wang H; Liu Y; Tian Q; Yang J; Lu R; Zhan S; Haukka J; Hong T
Diabetes Obes Metab; 2018 Apr; 20(4):910-920. PubMed ID: 29193572
[TBL] [Abstract][Full Text] [Related]
8. Treatment with incretins does not increase the risk of pancreatic diseases compared to older anti-hyperglycaemic drugs, when added to metformin: real world evidence in people with Type 2 diabetes.
Montvida O; Green JB; Atherton J; Paul SK
Diabet Med; 2019 Apr; 36(4):491-498. PubMed ID: 30306620
[TBL] [Abstract][Full Text] [Related]
9. Incretin therapies and risk of hospital admission for acute pancreatitis in an unselected population of European patients with type 2 diabetes: a case-control study.
Giorda CB; Picariello R; Nada E; Tartaglino B; Marafetti L; Costa G; Gnavi R
Lancet Diabetes Endocrinol; 2014 Feb; 2(2):111-5. PubMed ID: 24622714
[TBL] [Abstract][Full Text] [Related]
10. Association Between Incretin-Based Drugs and the Risk of Acute Pancreatitis.
Azoulay L; Filion KB; Platt RW; Dahl M; Dormuth CR; Clemens KK; Durand M; Hu N; Juurlink DN; Paterson JM; Targownik LE; Turin TC; Ernst P; ; Suissa S; Dormuth CR; Hemmelgarn BR; Teare GF; Caetano P; Chateau D; Henry DA; Paterson JM; LeLorier J; Levy AR; Ernst P; Platt RW; Sketris IS
JAMA Intern Med; 2016 Oct; 176(10):1464-1473. PubMed ID: 27479930
[TBL] [Abstract][Full Text] [Related]
11. Incretins, Diabetes, Pancreatitis and Pancreatic Cancer: What the GI specialist needs to know.
Forsmark CE
Pancreatology; 2016; 16(1):10-3. PubMed ID: 26795258
[TBL] [Abstract][Full Text] [Related]
12. Balancing benefits and risks in patients receiving incretin-based therapies: focus on cardiovascular and pancreatic side effects.
Haluzík M; Mráz M; Svačina Š
Drug Saf; 2014 Dec; 37(12):1003-10. PubMed ID: 25391858
[TBL] [Abstract][Full Text] [Related]
13. Pancreatic safety of incretin-based drugs--FDA and EMA assessment.
Egan AG; Blind E; Dunder K; de Graeff PA; Hummer BT; Bourcier T; Rosebraugh C
N Engl J Med; 2014 Feb; 370(9):794-7. PubMed ID: 24571751
[No Abstract] [Full Text] [Related]
14. Incretin-mimetics associated pancreatitis: evidence from the spontaneous adverse drug reactions reporting in Italy.
Delfino M; Motola D; Benini A; Franzè GP; Barotto M; Campi A; Monda VM
Expert Opin Drug Saf; 2014 Feb; 13(2):151-6. PubMed ID: 24219498
[TBL] [Abstract][Full Text] [Related]
15. Adverse drug reactions associated with the use of liraglutide in patients with type 2 diabetes--focus on pancreatitis and pancreas cancer.
Chalmer T; Almdal TP; Vilsbøll T; Knop FK
Expert Opin Drug Saf; 2015 Jan; 14(1):171-80. PubMed ID: 25363438
[TBL] [Abstract][Full Text] [Related]
16. [Cardiovascular safety of incretin-based antidiabetic treatment - results of completed clinical trials].
Jermendy G
Orv Hetil; 2016 Apr; 157(16):603-10. PubMed ID: 27063427
[TBL] [Abstract][Full Text] [Related]
17. Incretin-based therapies are associated with acute pancreatitis: Meta-analysis of large randomized controlled trials.
Roshanov PS; Dennis BB
Diabetes Res Clin Pract; 2015 Dec; 110(3):e13-7. PubMed ID: 26643128
[TBL] [Abstract][Full Text] [Related]
18. Potential harms of type 2 diabetes drugs have been ignored, finds BMJ investigation.
Kmietowicz Z
BMJ; 2013 Jun; 346():f3782. PubMed ID: 23757752
[No Abstract] [Full Text] [Related]
19. Incretin-based drugs and adverse pancreatic events: almost a decade later and uncertainty remains.
Azoulay L
Diabetes Care; 2015 Jun; 38(6):951-3. PubMed ID: 25998285
[TBL] [Abstract][Full Text] [Related]
20. Use of incretin agents and risk of pancreatic cancer: a population-based cohort study.
Knapen LM; van Dalem J; Keulemans YC; van Erp NP; Bazelier MT; De Bruin ML; Leufkens HG; Croes S; Neef C; de Vries F; Driessen JH
Diabetes Obes Metab; 2016 Mar; 18(3):258-65. PubMed ID: 26537555
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
